202 related articles for article (PubMed ID: 24437949)
1. Interaction of antidiabetic vanadium compounds with hemoglobin and red blood cells and their distribution between plasma and erythrocytes.
Sanna D; Serra M; Micera G; Garribba E
Inorg Chem; 2014 Feb; 53(3):1449-64. PubMed ID: 24437949
[TBL] [Abstract][Full Text] [Related]
2. Interaction of insulin-enhancing vanadium compounds with human serum holo-transferrin.
Sanna D; Micera G; Garribba E
Inorg Chem; 2013 Oct; 52(20):11975-85. PubMed ID: 24090437
[TBL] [Abstract][Full Text] [Related]
3. Characterization and biotransformation in the plasma and red blood cells of V(IV)O(2+) complexes formed by ceftriaxone.
Sanna D; Fabbri D; Serra M; Buglyó P; Bíró L; Ugone V; Micera G; Garribba E
J Inorg Biochem; 2015 Jun; 147():71-84. PubMed ID: 25601642
[TBL] [Abstract][Full Text] [Related]
4. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.
Sanna D; Micera G; Garribba E
Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643
[TBL] [Abstract][Full Text] [Related]
5. Speciation of potential anti-diabetic vanadium complexes in real serum samples.
Sanna D; Ugone V; Serra M; Garribba E
J Inorg Biochem; 2017 Aug; 173():52-65. PubMed ID: 28499214
[TBL] [Abstract][Full Text] [Related]
6. Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.
Sanna D; Ugone V; Pisano L; Serra M; Micera G; Garribba E
J Inorg Biochem; 2015 Dec; 153():167-177. PubMed ID: 26281973
[TBL] [Abstract][Full Text] [Related]
7. Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G.
Sanna D; Micera G; Garribba E
Inorg Chem; 2011 Apr; 50(8):3717-28. PubMed ID: 21434616
[TBL] [Abstract][Full Text] [Related]
8. Interaction of Vanadium(IV) Species with Ubiquitin: A Combined Instrumental and Computational Approach.
Ugone V; Sanna D; Sciortino G; Maréchal JD; Garribba E
Inorg Chem; 2019 Jun; 58(12):8064-8078. PubMed ID: 31140794
[TBL] [Abstract][Full Text] [Related]
9. ESI-MS Study of the Interaction of Potential Oxidovanadium(IV) Drugs and Amavadin with Model Proteins.
Ugone V; Sanna D; Sciortino G; Crans DC; Garribba E
Inorg Chem; 2020 Jul; 59(14):9739-9755. PubMed ID: 32585093
[TBL] [Abstract][Full Text] [Related]
10. Temperature and solvent structure dependence of VO2+ complexes of pyridine-N-oxide derivatives and their interaction with human serum transferrin.
Sanna D; Ugone V; Micera G; Garribba E
Dalton Trans; 2012 Jun; 41(24):7304-18. PubMed ID: 22576640
[TBL] [Abstract][Full Text] [Related]
11. A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding.
Gonçalves G; Tomaz I; Correia I; Veiros LF; Castro MM; Avecilla F; Palacio L; Maestro M; Kiss T; Jakusch T; Garcia MH; Pessoa JC
Dalton Trans; 2013 Sep; 42(33):11841-61. PubMed ID: 23677414
[TBL] [Abstract][Full Text] [Related]
12. Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum.
Sanna D; Bíró L; Buglyó P; Micera G; Garribba E
J Inorg Biochem; 2012 Oct; 115():87-99. PubMed ID: 22926028
[TBL] [Abstract][Full Text] [Related]
13. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of vanadium(IV) complexes with cis-inositol in aqueous solution and in the solid-state.
Morgenstern B; Kutzky B; Neis C; Stucky S; Hegetschweiler K; Garribba E; Micera G
Inorg Chem; 2007 May; 46(10):3903-15. PubMed ID: 17419616
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of V(IV)O complexes of picolinate and pyrazine derivatives. Behavior in the solid state and aqueous solution and biotransformation in the presence of blood plasma proteins.
Koleša-Dobravc T; Lodyga-Chruscinska E; Symonowicz M; Sanna D; Meden A; Perdih F; Garribba E
Inorg Chem; 2014 Aug; 53(15):7960-76. PubMed ID: 25013935
[TBL] [Abstract][Full Text] [Related]
16. A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.
Sanna D; Buglyó P; Micera G; Garribba E
J Biol Inorg Chem; 2010 Aug; 15(6):825-39. PubMed ID: 20339887
[TBL] [Abstract][Full Text] [Related]
17. Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug.
Sanna D; Ugone V; Micera G; Buglyó P; Bíró L; Garribba E
Dalton Trans; 2017 Jul; 46(28):8950-8967. PubMed ID: 28640312
[TBL] [Abstract][Full Text] [Related]
18. Interaction of vanadium(IV) with human serum apo-transferrin.
Mehtab S; Gonçalves G; Roy S; Tomaz AI; Santos-Silva T; Santos MF; Romão MJ; Jakusch T; Kiss T; Pessoa JC
J Inorg Biochem; 2013 Apr; 121():187-95. PubMed ID: 23411030
[TBL] [Abstract][Full Text] [Related]
19. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
[TBL] [Abstract][Full Text] [Related]
20. Complex formation in aqueous solution and in the solid state of the potent insulin-enhancing V(IV)O2+ compounds formed by picolinate and quinolinate derivatives.
Lodyga-Chruscinska E; Micera G; Garribba E
Inorg Chem; 2011 Feb; 50(3):883-99. PubMed ID: 21226475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
